In vitro induction of specific CD8 + T lymphocytes by tumor-associated antigenic peptides in patients with oral squamous cell carcinoma

Takeshi Toyoshima, Kumamaru Wataru, Hayashida Jun-Nosuke, Masafumi Moriyama, ryoji kitamura, Hideaki Tanaka, Akira Yamada, Kyogo Itoh, Seiji Nakamura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aim of this study was to clarify candidate peptides for peptide-based specific immunotherapy of patients with oral squamous cell carcinoma (SCC). Thirteen peptides were examined for in vitro induction of peptide-specific CD8 + T lymphocyte (CD8 +TL) activity in peripheral blood mononuclear cells from 35 patients with oral SCC. A correlation between the induction ability of CD8 +TL and in vivo immune response of host was carried out immunohistochemically in 23 patients. Peptide-specific activities of CD8 +TL for at least one peptide were detectable in 21/35 patients (60.0%). The potent peptides were SART-1 690 in 9/35 (25.7%), SART-2 93, and ART4 75 in 7/35 (20.0%), respectively. In the 9 patients with SART-1 690-specific activity, the whole of activities was significantly inducible for more number of other peptides compared to that in 26 patients without the activity (P=0.035). Cellular responses in 7 patients with SART-1 690-specific activity were significantly stronger than those in 16 patients without the activity (P=0.027). Furthermore, the number of CD3 + T cells around the SCC was also significantly different between the 2 groups of patients (P=0.041). In conclusion, SART-1 690, SART-2 93, and ART4 75 could be applicable as peptide-based specific immunotherapies for the majority of patients with oral SCC.

Original languageEnglish
Pages (from-to)86-91
Number of pages6
JournalCancer Letters
Volume322
Issue number1
DOIs
Publication statusPublished - Sep 1 2012

Fingerprint

Squamous Cell Carcinoma
T-Lymphocytes
Peptides
Neoplasms
Immunotherapy
In Vitro Techniques
Blood Cells

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

In vitro induction of specific CD8 + T lymphocytes by tumor-associated antigenic peptides in patients with oral squamous cell carcinoma. / Toyoshima, Takeshi; Wataru, Kumamaru; Jun-Nosuke, Hayashida; Moriyama, Masafumi; kitamura, ryoji; Tanaka, Hideaki; Yamada, Akira; Itoh, Kyogo; Nakamura, Seiji.

In: Cancer Letters, Vol. 322, No. 1, 01.09.2012, p. 86-91.

Research output: Contribution to journalArticle

@article{0851faa3e93542daa136ac67da702ddd,
title = "In vitro induction of specific CD8 + T lymphocytes by tumor-associated antigenic peptides in patients with oral squamous cell carcinoma",
abstract = "The aim of this study was to clarify candidate peptides for peptide-based specific immunotherapy of patients with oral squamous cell carcinoma (SCC). Thirteen peptides were examined for in vitro induction of peptide-specific CD8 + T lymphocyte (CD8 +TL) activity in peripheral blood mononuclear cells from 35 patients with oral SCC. A correlation between the induction ability of CD8 +TL and in vivo immune response of host was carried out immunohistochemically in 23 patients. Peptide-specific activities of CD8 +TL for at least one peptide were detectable in 21/35 patients (60.0{\%}). The potent peptides were SART-1 690 in 9/35 (25.7{\%}), SART-2 93, and ART4 75 in 7/35 (20.0{\%}), respectively. In the 9 patients with SART-1 690-specific activity, the whole of activities was significantly inducible for more number of other peptides compared to that in 26 patients without the activity (P=0.035). Cellular responses in 7 patients with SART-1 690-specific activity were significantly stronger than those in 16 patients without the activity (P=0.027). Furthermore, the number of CD3 + T cells around the SCC was also significantly different between the 2 groups of patients (P=0.041). In conclusion, SART-1 690, SART-2 93, and ART4 75 could be applicable as peptide-based specific immunotherapies for the majority of patients with oral SCC.",
author = "Takeshi Toyoshima and Kumamaru Wataru and Hayashida Jun-Nosuke and Masafumi Moriyama and ryoji kitamura and Hideaki Tanaka and Akira Yamada and Kyogo Itoh and Seiji Nakamura",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.canlet.2012.02.016",
language = "English",
volume = "322",
pages = "86--91",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - In vitro induction of specific CD8 + T lymphocytes by tumor-associated antigenic peptides in patients with oral squamous cell carcinoma

AU - Toyoshima, Takeshi

AU - Wataru, Kumamaru

AU - Jun-Nosuke, Hayashida

AU - Moriyama, Masafumi

AU - kitamura, ryoji

AU - Tanaka, Hideaki

AU - Yamada, Akira

AU - Itoh, Kyogo

AU - Nakamura, Seiji

PY - 2012/9/1

Y1 - 2012/9/1

N2 - The aim of this study was to clarify candidate peptides for peptide-based specific immunotherapy of patients with oral squamous cell carcinoma (SCC). Thirteen peptides were examined for in vitro induction of peptide-specific CD8 + T lymphocyte (CD8 +TL) activity in peripheral blood mononuclear cells from 35 patients with oral SCC. A correlation between the induction ability of CD8 +TL and in vivo immune response of host was carried out immunohistochemically in 23 patients. Peptide-specific activities of CD8 +TL for at least one peptide were detectable in 21/35 patients (60.0%). The potent peptides were SART-1 690 in 9/35 (25.7%), SART-2 93, and ART4 75 in 7/35 (20.0%), respectively. In the 9 patients with SART-1 690-specific activity, the whole of activities was significantly inducible for more number of other peptides compared to that in 26 patients without the activity (P=0.035). Cellular responses in 7 patients with SART-1 690-specific activity were significantly stronger than those in 16 patients without the activity (P=0.027). Furthermore, the number of CD3 + T cells around the SCC was also significantly different between the 2 groups of patients (P=0.041). In conclusion, SART-1 690, SART-2 93, and ART4 75 could be applicable as peptide-based specific immunotherapies for the majority of patients with oral SCC.

AB - The aim of this study was to clarify candidate peptides for peptide-based specific immunotherapy of patients with oral squamous cell carcinoma (SCC). Thirteen peptides were examined for in vitro induction of peptide-specific CD8 + T lymphocyte (CD8 +TL) activity in peripheral blood mononuclear cells from 35 patients with oral SCC. A correlation between the induction ability of CD8 +TL and in vivo immune response of host was carried out immunohistochemically in 23 patients. Peptide-specific activities of CD8 +TL for at least one peptide were detectable in 21/35 patients (60.0%). The potent peptides were SART-1 690 in 9/35 (25.7%), SART-2 93, and ART4 75 in 7/35 (20.0%), respectively. In the 9 patients with SART-1 690-specific activity, the whole of activities was significantly inducible for more number of other peptides compared to that in 26 patients without the activity (P=0.035). Cellular responses in 7 patients with SART-1 690-specific activity were significantly stronger than those in 16 patients without the activity (P=0.027). Furthermore, the number of CD3 + T cells around the SCC was also significantly different between the 2 groups of patients (P=0.041). In conclusion, SART-1 690, SART-2 93, and ART4 75 could be applicable as peptide-based specific immunotherapies for the majority of patients with oral SCC.

UR - http://www.scopus.com/inward/record.url?scp=84861459705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861459705&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2012.02.016

DO - 10.1016/j.canlet.2012.02.016

M3 - Article

C2 - 22366580

AN - SCOPUS:84861459705

VL - 322

SP - 86

EP - 91

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -